Interim results from the ongoing OPTIMIZE-1 phase II study of mitazalimab in combination with chemotherapy, mFOLFIRINOX, in first line metastatic pancreatic cancer demonstrate an objective response rate of 52% in 23 evaluable patients, as per the Response Evaluation Criteria in Solid Tumors.
Cedars-Sinai investigators who previously developed an imaging tool that used artificial intelligence to predict pancreatic cancer are now working to adapt that tool specifically for Black patients, who have disproportionately high rates of the disease.
